ASML's bottleneck advantage: can EUV scarcity still compound?
An ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
26Results20Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
ASML Holding: the company behind the chip industry's narrowest bottleneck
A Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
OpenAdvanced Biomed: The No-Revenue Biotech That Just Swerved Into AI
Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenTSMC's AI foundry test: growth, capex, and geopolitical risk
A TSMC five-year double thesis focused on advanced-node foundry leadership, advanced packaging, AI customer demand, capex, margins, and Taiwan risk.
OpenTSMC: the AI foundry moat with a geopolitical discount
A Coverage Bootstrap TSMC company evaluation covering advanced-node foundry leadership, CoWoS, customers, margins, capex, global fabs, Taiwan risk, and valuation setup.
OpenNVIDIA's next five years: can AI earnings outrun valuation risk?
A filing-led NVDA five-year double thesis focused on data-center demand, CUDA lock-in, networking attach, margin durability, and valuation risk.
OpenNVIDIA: the AI factory tollbooth, priced for proof
A Coverage Bootstrap NVIDIA company evaluation covering AI accelerators, CUDA, networking, data-center concentration, margins, export controls, valuation risk, and proof gates.
OpenMicron's HBM cycle: can AI memory change the boom-bust math?
A Micron five-year double thesis focused on HBM demand, DRAM/NAND cycle discipline, capital intensity, and whether AI memory improves through-cycle economics.
OpenMicron: AI memory scarcity is rewriting the cycle
A refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenBroadcom's AI cash-flow test: custom chips, Ethernet, and VMware
A Broadcom five-year double thesis focused on custom AI silicon, Ethernet networking, VMware free cash flow, customer concentration, and integration risk.
OpenBroadcom: custom AI silicon plus VMware cash flow
A Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenAIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAIHS: after two disposals, the stock is a financing test
Senmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAGRZ: a vertical-farm microcap with a receivables test
Agroz has a real Malaysian CEA business and fast disclosed H1 2025 revenue growth, but AGRZ is a limited-disclosure microcap until it files FY2025 annual results, collects receivables and proves cash conversion.
OpenAGAE: the esports arena is now a listing-compliance story
Allied still has HyperX Arena Las Vegas, Z-Tech mobile games, and a balance-sheet cushion, but the current thesis is about the late 10-K, Nasdaq delisting risk, reverse-split vote, Knighted settlement, and whether revenue can ever catch the cost base.
OpenAeva: the LiDAR design-win story racing a $35M quarterly loss
Aeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2
OpenAditxt: The Biotech Roll-Up Fighting Nasdaq Before It Fights Disease
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?
Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAnalog Devices: the analog chip giant riding AI racks while factories thaw
ADI is not a pure AI stock. It is a cash-rich analog semiconductor leader where industrial recovery, automotive resilience, and data-center infrastructure orders are now arriving at the same time.
OpenAclarion: the $19M cash pile chasing a tiny Nociscan revenue line
Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
Open